Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07207395) titled 'A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The Christ Hospital
Condition:
Lung Cancer (NSCLC)
Intervention:
Drug: JBI-802
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: April 29, 2025
Target Sample Size: 30
Countries of Recruitment:
United States
To know more, visit https://clinic...